Circulating free DNA (cfDNA) derived from urine has emerged as a promising biomarker in the field of non-invasive diagnostics, particularly in oncology, nephrology, and other areas of medical research. With advances in next-generation sequencing (NGS) and other molecular techniques, such as droplet digital PCR (ddPCR), the analysis of cfDNA from urine holds the potential to revolutionize diagnostics, enabling earlier detection, better risk stratification, and more precise monitoring of therapeutic efficacy with minimal patient burden.
In this webinar, you will:
• Understand the importance of pre-analytical sample preservation for cfDNA extractions.
• Explore a complete workflow from urine collection and preservation to cfDNA extraction and subsequent downstream implementation.
• Analyze droplet digital PCR data from urinary cfDNA for detection of gene variants at different allelic frequencies (AF).
The combination of sample stabilization, high sensitivity cfDNA purification, and ability to detect mutations as low as 0.1% AF using ddPCR makes this an attractive solution for cfDNA analysis in clinical and research settings.
There will be a Q&A session to answer questions. Please bring them to the live event.